Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Anti-HIV drug regimens have dramatically improved the rates of prevention of mother-to-child
transmission (MTCT) of HIV in developed countries. However, little is known of the
effectiveness of such regimens in developing countries, such as Botswana. This study will
determine whether Trizivir (TZV), a single pill containing abacavir sulfate, lamivudine, and
zidovudine (ABC/3TC/ZDV), or lopinavir/ritonavir (LPV/r) and lamivudine/zidovudine (3TC/ZDV)
is more effective in reducing HIV-1 viral load and preventing MTCT among HIV infected
pregnant women in Botswana.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Harvard School of Public Health Harvard School of Public Health (HSPH)
Treatments:
Abacavir Lamivudine Lamivudine, zidovudine drug combination Lopinavir Nevirapine Ritonavir Zidovudine